FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to-severe Sjögren’s disease, which could be the first targeted therapy ever ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback